Eli Lilly and Company (LLY)vsP3 Health Partners Inc (PIII)
LLY
Eli Lilly and Company
$1,183.76
+2.68%
HEALTHCARE · Cap: $1.03T
PIII
P3 Health Partners Inc
$7.05
-0.56%
HEALTHCARE · Cap: $1.61B
Smart Verdict
WallStSmart Research — data-driven comparison
Eli Lilly and Company generates 5201% more annual revenue ($79.67B vs $1.50B). LLY leads profitability with a 33.5% profit margin vs -6.5%. LLY earns a higher WallStSmart Score of 76/100 (B+).
LLY
Strong Buy76
out of 100
Grade: B+
PIII
Hold38
out of 100
Grade: F
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 79 in profit
Keeps 34 of every $100 in revenue as profit
Strong operational efficiency at 54.2%
Revenue surging 47.7% year-over-year
Earnings expanding 26.2% YoY
No standout strengths identified
Areas to Watch
Premium valuation, high expectations priced in
Elevated debt levels
Trading at 31.2x book value
0.0% earnings growth
Smaller company, higher risk/reward
Elevated debt levels
Weak financial health signals
Comparative Analysis Report
WallStSmart ResearchBull Case : LLY
The strongest argument for LLY centers on Market Cap, Return on Equity, Profit Margin. Profitability is solid with margins at 33.5% and operating margin at 54.2%. Revenue growth of 47.7% demonstrates continued momentum.
Bull Case : PIII
PIII has a balanced fundamental profile.
Bear Case : LLY
The primary concerns for LLY are P/E Ratio, Debt/Equity, Price/Book. Debt-to-equity of 1.62 is elevated, increasing financial risk.
Bear Case : PIII
The primary concerns for PIII are EPS Growth, Market Cap, Debt/Equity. Debt-to-equity of 1.80 is elevated, increasing financial risk.
Key Dynamics to Monitor
LLY profiles as a growth stock while PIII is a turnaround play — different risk/reward profiles.
PIII carries more volatility with a beta of 1.62 — expect wider price swings.
LLY is growing revenue faster at 47.7% — sustainability is the question.
LLY generates stronger free cash flow (7.8B), providing more financial flexibility.
Bottom Line
LLY scores higher overall (76/100 vs 38/100), backed by strong 33.5% margins and 47.7% revenue growth. Both earn "Strong Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Eli Lilly and Company
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Eli Lilly and Company is an American pharmaceutical company headquartered in Indianapolis, Indiana, with offices in 18 countries. Its products are sold in approximately 125 countries.
Visit Website →P3 Health Partners Inc
HEALTHCARE · MEDICAL CARE FACILITIES · USA
P3 Health Partners Inc (PIII) is a forward-thinking healthcare organization dedicated to enhancing care quality and minimizing costs through innovative, data-driven methodologies. Specializing in value-based care models, the company leverages telehealth technologies and advanced analytics to deliver tailored healthcare solutions, particularly targeting underserved populations. By collaborating with community organizations and maintaining a robust network of primary care providers and specialists, PIII addresses the growing demand for efficient healthcare services. With a steadfast commitment to high-quality, cost-effective care, PIII is well-positioned to thrive in the evolving healthcare environment.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?